AI Company Ignota Labs Repurposes Failed Drugs Using Machine Learning

Ignota Labs applies machine-learning algorithms to analyze failed pharmaceutical compounds and determine the reasons for their clinical trial failures, then re-engineers the most promising candidates for potential success. Founded by Layla Hosseini-Gerami (chief data-science officer), Jordan Lane, and Sam Windsor, the company combines chemistry, bioinformatics, and data science to understand how drugs affect the body at the molecular level. Hosseini-Gerami, who was recognized on Forbes' '30 under 30' list in April 2025, developed her expertise through an internship at drug-discovery software company Optibrium and a PhD at Cambridge University focused on computational algorithms that identify biological targets and drug pathways. The company's approach addresses a longstanding challenge in drug discovery: many approved compounds lack clear understanding of their mechanisms of action. With $6.9 million in funding secured in February 2025, Ignota Labs has developed a promising pipeline of therapies targeting autoimmune diseases and blood cancers.